Madrigal Pharmaceuticals, Inc. Common Stock

Day range

$433.31 – $453.55

Open

$453.55

Prev close

$453.34

Volume

234.85K

Market cap

$10.47B

Shares out

23.1M

P/E

—

P/S

8.16

P/B

20.00

P/FCF

—

ROE

-62.1%

ROA

-26.1%

Debt/Equity

0.65

Div yield

0.00%

As of Oct 22, 2026

• Board of directorsAug 12, 2026

  the Board of Directors (the "Board") of Madrigal Pharmaceuticals, Inc. (the "Company") expanded the size of the Board from eight to nine members and, following the recommendation of its Nominating and Governance Committee, elected John C. Reed, M.D., Ph.D. to fill the newly created vacancy on the Board effective as of August 11, 2026. Dr. Reed will serve as a Class II director with a term expiring at the annual meeting of stockholders to be held in 2027 or until his successor is duly elected and qualified. Dr. Reed has been appointed to the Science and Technology Committee of the Board.

• Executive leadershipJun 17, 2026

  On June 17, 2026, the Company entered into a consulting agreement with Dr. Rebecca Taub (the "Taub Consulting Agreement"). Pursuant to the Taub Consulting Agreement, effective as of July 1, 2026, Dr. Taub will transition from an employee of the Company to a consultant.

• Material agreementsJan 30, 2026

  Madrigal Pharmaceuticals, Inc. (the "Company"), F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (together, "Roche") entered into the First Amendment (the "Amendment") to the Research, Development, and Commercialization Agreement dated as of December 18, 2008 between the Company and Roche.

• Executive leadershipDec 11, 2025

  Pursuant to an offer letter, Ms. Thakkar will receive an annual base salary of $450,000. In addition, Ms. Thakkar will be eligible to receive (i) an annual performance-based bonus with a target opportunity equal to 40% of her base salary, based on the achievement of corporate and individual targets determined by the Compensation Committee of the Company's Board of Directors. In connection with her appointment, Ms. Thakkar will receive an initial equity award with a target aggregate value of $1,932,000.

• Deal agreementsJul 30, 2025

  Madrigal Pharmaceuticals Enters into Exclusive Global License Agreement for Oral GLP-1 Receptor Agonist with CSPC Pharmaceutical Group Limited.

Days to cover

9.8

Short interest

2.4M

Avg volume

245K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Metabolic Dysfunction-Associated Steatohepatitis Clinical Trial and Competitive Landscape Expands as 180+ Companies Target New Treatment Options | DelveInsight
  positiveGlobeNewswire Inc.· Oct 20, 2026
• Can NVO's Semaglutide Push Create Growth Beyond Cardiometabolic Care?
  neutralZacks Investment Research· Oct 7, 2026
• 3 Under-the-Radar Stocks to Buy and Hold for a Decade
  positiveThe Motley Fool· Jun 16, 2026
• Madrigal Pharmaceuticals to Release First-Quarter 2026 Financial Results and Host Webcast on May 6, 2026
  positiveGlobeNewswire Inc.· Apr 22, 2026
• The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step
  positiveBenzinga· Mar 31, 2026